We are live on ! Find out more
STML

Stemline Therapeutics, Inc.
STML

Delisted

STML was delisted on the 9th of June, 2020.

Back to rankings

92 hedge funds and large institutions have $195M invested in Stemline Therapeutics, Inc. in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 39 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 19

21% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 14

2% more funds holding

Funds holding: 90 → 92 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

31% less call options, than puts

Call options by funds: $1.6M | Put options by funds: $2.31M

42% less capital invested

Capital invested by funds: $337M → $195M (-$143M)

Holders
92
Holders Change
+2
Holders Change %
+2.22%
% of All Funds
2.05%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
17
Increased
39
Reduced
19
Closed
14
Calls
$1.6M
Puts
$2.31M
Net Calls
-$717K
Net Calls Change
+$3.11M

Top Buyers

Rank Fund Capital Flow
1
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
+$12.8M
2
ELI
Empire Life Investments
Ontario, Canada
+$3.56M
3
PC
Polar Capital
United Kingdom
+$3.22M
4
Axa
Axa
France
+$2.98M
5
PC
Pier Capital
Connecticut
+$2.23M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$20.6M
2
LSC
Lyon Street Capital
California
-$8.93M
3
Citadel Advisors
Citadel Advisors
Florida
-$5.67M
4
Invesco
Invesco
Georgia
-$1.5M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$1.28M +$366K +28,198 +26%
CWG
27
C WorldWide Group
Denmark
$1.26M -$609K -46,981 -26%
UBS Group
28
UBS Group
Switzerland
$1.01M +$949K +73,155 +219%
TCIM
29
TIAA CREF Investment Management
New York
$913K +$589K +45,387 +89%
Citigroup
30
Citigroup
New York
$741K +$543K +41,897 +116%
Two Sigma Investments
31
Two Sigma Investments
New York
$702K -$549K -42,316 -36%
Alkeon Capital Management
32
Alkeon Capital Management
New York
$665K +$389K +30,000 +75%
Charles Schwab
33
Charles Schwab
California
$611K -$3.42K -264 -0.4%
FI
34
Fosun International
China
$572K +$752K +58,000 New
TA
35
Teachers Advisors
New York
$541K +$65.1K +5,021 +10%
Two Sigma Advisers
36
Two Sigma Advisers
New York
$528K -$587K -45,300 -45%
Morgan Stanley
37
Morgan Stanley
New York
$473K -$33.3K -2,568 -5%
Swiss National Bank
38
Swiss National Bank
Switzerland
$468K +$639K +49,300 New
Jacobs Levy Equity Management
39
Jacobs Levy Equity Management
New Jersey
$431K +$589K +45,413 New
Ameriprise
40
Ameriprise
Minnesota
$427K -$29.6K -2,280 -5%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$421K +$13.2K +1,015 +2%
TI
42
Telemetry Investments
New York
$395K +$539K +41,588 New
Barclays
43
Barclays
United Kingdom
$381K +$318K +24,497 +157%
Goldman Sachs
44
Goldman Sachs
New York
$374K +$257K +19,798 +101%
SAM
45
Sectoral Asset Management
Quebec, Canada
$369K +$263K +20,300 +110%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$353K +$154K +11,911 +47%
AllianceBernstein
47
AllianceBernstein
Tennessee
$347K +$84.3K +6,500 +22%
Simplex Trading
48
Simplex Trading
Illinois
$344K +$351K +27,037 +292%
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$299K – – –
VEA
50
Virtus ETF Advisers
New York
$282K +$38.7K +2,982 +11%
1
2
3 4 5

STML Hedge Fund Activity: Q4 2018 in Review

92 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q4 2018, worth a combined $195M — down 42% from $337M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new STML positions and 14 closed out — a net gain of 3 holders — while 39 added to existing stakes and 19 trimmed.

The largest buyer was Manulife (Manufacturers Life Insurance), adding an estimated $12.8M. The largest seller was Consonance Capital Management, cutting an estimated $20.6M.

  • 92 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q4 2018, up from 90 in Q3 2018.
  • Funds reported $195M of Stemline Therapeutics, Inc. stock for Q4 2018, down 42% quarter-over-quarter.
  • 17 funds opened new Stemline Therapeutics, Inc. positions in Q4 2018 and 14 closed out, a net change of +3 holders.
  • The largest Stemline Therapeutics, Inc. buyer in Q4 2018 was Manulife (Manufacturers Life Insurance), an estimated $12.8M added.
  • The largest Stemline Therapeutics, Inc. seller in Q4 2018 was Consonance Capital Management, an estimated $20.6M sold.

Based on aggregated 13F filings for Q4 2018.